LEADER 01380nam--2200433---450- 001 990001312320203316 005 20130319145057.0 035 $a000131232 035 $aUSA01000131232 035 $a(ALEPH)000131232USA01 035 $a000131232 100 $a20031219d1965----km-y0itay0103----ba 101 0 $aspa 102 $aES 105 $a||||||||001yy 200 1 $aGeneraciones y semblanzas$fFernan Perez de Guzman$gedition critica por R. B. Tate 210 $aLondon$cTamesis books$d1965 215 $aXXVII, 112 p.$d24 cm 225 2 $aColección Támesis$xSerie B, textos 410 0$aColección Támesis$12001$xSerie B, textos 454 1$12001 461 1$1001-------$12001 676 $a920.9 700 1$aPEREZ DE GUZMAN,$bFernan <1388?-1470>$0557538 702 1$aTATE,$bR. B. 801 0$aIT$bsalbc$gISBD 912 $a990001312320203316 951 $aVI.5. Coll.17/ 5(II sp C coll 41/2)$b121 L.M.$cII sp 959 $aBK 969 $aUMA 979 $aSIAV6$b10$c20031219$lUSA01$h1636 979 $aSIAV6$b10$c20031219$lUSA01$h1637 979 $aPATRY$b90$c20040406$lUSA01$h1733 979 $aCOPAT6$b90$c20050701$lUSA01$h1515 979 $aPATRY$b90$c20130319$lUSA01$h1450 979 $aCHIARA$b90$c20140210$lUSA01$h1142 979 $aCHIARA$b90$c20140210$lUSA01$h1144 996 $aGeneraciones y semblanzas$9928893 997 $aUNISA LEADER 03265nam 2200433 450 001 9910830837103321 005 20230809233537.0 010 $a1-118-94063-6 010 $a1-118-94062-8 010 $a1-118-94064-4 035 $a(CKB)4330000000007601 035 $a(MiAaPQ)EBC4770361 035 $a(DLC) 2016020707 035 $a(EXLCZ)994330000000007601 100 $a20170104h20172017 uy 0 101 0 $aeng 135 $aurcnu|||||||| 181 $2rdacontent 182 $2rdamedia 183 $2rdacarrier 200 00$aBiosimilars of monoclonal antibodies $ea practical guide to manufacturing, preclinical, and clinical development /$fedited by Cheng Liu, K. John Morrow Jr 210 1$aHoboken, New Jersey :$cWiley,$d2017. 210 4$d©2017 215 $a1 online resource (723 pages) $cillustrations (some color) 311 $a1-118-66231-8 320 $aIncludes bibliographical references and index. 327 $aThe history of therapeutic monoclonal antibodies / Regis Sodoyer -- Structure, classification and naming of therapeutic monoclonal antibodies / Zhinan Xia -- Mechanism of action for therapeutic antibodies / Yu Zhou and James D. Marks -- Therapeutic monoclonal antibodies and their targets / Maurizio Chiriva-Internati, et al -- Antibody post-translational modifications / Roy Jefferis -- The pharmacology, pharmacokinetics, and pharmacodynamics of antibodies / Ningning Xu, Meimei Liu, Margaret Liu -- Monoclonal antibodies : applications in clinical oncology / Jeanene ("Gigi") Robison -- Development of biosimilar rituximab and clinical experience / Reena Nair -- Monoclonal antibodies for infectious diseases / Steven J. Projan -- Monoclonal antibodies for musculoskeletal, CNS, and other diseases / Junming Yie and Tao Wu -- Manufacture of recombinant therapeutic proteins using chinese hamster ovary cells in large-scale bioreactors : history, methods and perspectives / Florian M. Wurm and Maria De Jesus -- Process development / Samuel D. Stimple and David W. Wood -- Biosimilars and biobetters : impact on biopharmaceutical manufacturing and CMOs / Ronald A. Rader -- Cell line and cell culture development for biosimilar antibody drug manufacturing / Jianguo Yang -- Product analysis of biosimilar antibodies / Weidong Jiang, Scott Liu and Ziyang Zhong -- Bioanalytical development / Rafiq Islam -- Preclinical and clinical development of biosimilar antibodies / Joa?o Eurico Fonseca and Joa?o Gonc?alves -- Regulatory issues / Clarinda Islam -- Legal considerations / K. Lance Anderson, Jennifer R. Moore Meline, and Jonathan D. Ball -- ADCC enhancement technologies for next generation therapeutic antibodies / Cheng Liu and Su Yan -- Biosimilar antibody half-life : engineering for optimal performance / K. John Morrow, Jr -- Technologies for antibody drug conjugation / Patrick G. Holder and David Rabuka. 606 $aMonoclonal antibodies$xDiagnostic use 615 0$aMonoclonal antibodies$xDiagnostic use. 676 $a574.293 702 $aLiu$b Cheng 702 $aMorrow$b K. John$cJr., 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910830837103321 996 $aBiosimilars of monoclonal antibodies$93964750 997 $aUNINA